Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 5/20 | 0.46 |
| ▸ | EGFR | P00533 | 8/20 | 0.46 |
| ▸ | KRAS | P01116 | 4/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | LDHB | P07195 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4373030 | 0.84 | HTR7 (0.49) | EGFRLDHALDHB | |
| SCHEMBL4372989 | 0.84 | CSF1R (0.48) | SOS1EGFRABCB1 | |
| SCHEMBL4381611 | 0.84 | MEN1 (0.43) | SOS1EGFRKRASLDHALDHB | |
| SCHEMBL4375549 | 0.82 | TLR7 (0.52) | SOS1EGFRKRASLDHALDHB | |
| SCHEMBL4379483 | 0.82 | DHFR (0.52) | EGFRDHFRABCB1 | |
| SCHEMBL7098780 | 0.82 | PLK1 (0.42) | SOS1EGFRKRASLDHALDHB | |
| SCHEMBL4375552 | 0.82 | HTR7 (0.50) | EGFR | |
| SCHEMBL4374758 | 0.81 | HTR7 (0.54) | — | |
| SCHEMBL4379084 | 0.81 | HTR7 (0.54) | — | |
| SCHEMBL4374821 | 0.81 | HTR7 (0.43) | SOS1KRASLDHALDHB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280781-B1 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2009-11-18 | — | — | EP | claimed |
| US-20020032199-A1 | 5-HT7 receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-14 | — | — | US | claimed |
| EP-1280781-B1 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2009-11-18 | — | — | EP | disclosed |
| US-6630469-B2 | Amino-pyrimidine and amino-triazine derivatives having 5-HT7 antagonist activity for the treatment of sleeping disorders, depression, schizophrenia, anxiety, obsessive compulsive disorders, cicadian rhythm disorders and hypertension | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-07 | — | — | US | disclosed |
| EP-1280781-A4 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2003-08-06 | — | — | EP | disclosed |
| EP-1280781-A1 | 5-HT 7 RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2003-02-05 | — | — | EP | disclosed |
| US-20020032199-A1 | 5-HT7 receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-14 | — | — | US | disclosed |
| WO-2001085701-A1 | 5-HT7 RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032199-A1 | 5-HT7 receptor antagonists | HTR7, HTR5A, HTR1A | SOS1 379/4885EGFR 2920/4885KRAS 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.